|
|
|
2010³â05¿ù06ÀÏ 00½Ã00ºÐ |
|
|
|
|
Áß¾Ó´ë ÀÌÇö¿õ-¿¬¼¼´ë ¹é¿ëÇÑ ±³¼ö, °£ÇÐȸ Çмú³í¹®»ó ¼ö»ó
|
|
Áß¾Ó´ëÀÇ´ë ¼Òȱ⳻°ú ÀÌÇö¿õ ±³¼ö¿Í ¿¬¼¼ÀÇ´ë ³»°úÇб³½Ç ¹é¿ëÇÑ ±³¼ö°¡ ´ëÇÑ°£ÇÐȸ(ȸÀå ÃÖº´ÀÎ ¼¿ï´ëº´¿ø, ÀÌ»çÀå À¯º´Ã¶ »ï¼º¼¿ïº´¿ø)°¡ ¼±Á¤ÇÏ´Â GSK Çмú³í¹®»ó ¼ö»óÀÚ·Î °áÁ¤µÆ´Ù.
ÇÐȸ´Â Áö³ 2009³â 3¿ùºÎÅÍ 2010³â 2¿ù±îÁö SCI¿¡ µîÀçµÈ ±¹Á¦ÇмúÁö¿¡ °ÔÀçµÈ Á¤È¸¿øÀ» ´ë»óÀ¸·Î ¼ö»óÀÚ¸¦ °ø¸ðÇßÀ¸¸ç, Áö³ 4¿ù 7ÀÏ ¼ÒÁýµÈ ½É»çÀ§¿øȸ¿¡¼ ÃÑ 6¸íÀÇ ÀÀ¸ðÀÚ Áß 2¸íÀ» ¼±Á¤Çß´Ù.
ÀÌÇö¿õ ±³¼ö´Â ‘Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sutained virologic response in HBeAg-positive choronic hepatitis B’¶ó´Â ÁÖÁ¦ÀÇ ³í¹®À¸·Î Hepatology¿¡ ¹ßÇ¥µÆ´Ù.
¹é¿ëÇÑ ±³¼ö´Â ‘Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats’¶ó´Â ÁÖÁ¦·Î GUT¿¡ ¹ßÇ¥µÆ´Ù.
|
|
|
|
|
|